Company intelligence / Profile preview

QED Pharmaceuticals

Palo Alto, California, United States

Ownership: Private
Employees: ~40
Development stage: Commercial

Overview

Infigratinib, a selective oral FGFR1–3 tyrosine kinase inhibitor, has demonstrated clinical efficacy in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 alterations. It received FDA breakthrough therapy designation for achondroplasia and is currently being evaluated in Phase 2/Phase 3 studies for skeletal dysplasias including achondroplasia and hypochondroplasia. An NDA was submitted to the FDA for second-line cholangiocarcinoma in 2020; first approval occurred May 28, 2021.

Therapeutic areas: OncologyRare Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Helsinn Group – co-development/commercialization of infigratinib in oncology indications

Beyond the preview

Go deeper on QED Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QED Pharmaceuticals.

Explore the full profile